Market Overview

Illumina Launches Infinium® HumanCore Arrays for Economical Large-Scale Genetic Studies

SAN DIEGO--(BUSINESS WIRE)--

Illumina, Inc. (NASDAQ: ILMN) today launched the Infinium HumanCore BeadChip family of products. With content developed in collaboration with several leading research institutions, the customizable Infinium HumanCore and Infinium HumanCoreExome BeadChips support cost-effective, large-scale genotyping and screening studies such as those performed by biobanks, genome centers, and core labs. Based on Illumina's proven Infinium assay, the BeadChips enable genotyping of markers found across diverse populations, making them ideal for researchers engaged in population genetics studies around the world.

“These powerful, cost-effective arrays were specifically designed to make genotyping accessible to a wider range of researchers and laboratories,” said Christian Henry, Senior Vice President and General Manager, Genomic Solutions at Illumina. “Infinium HumanCore BeadChips combine affordability and high-throughput sample processing using the industry's best multi-sample array. The high-quality, genome-wide information they deliver can be used for a variety of downstream applications.”

Both customizable arrays include content important for disease research, including association studies and copy number variant discovery and analysis. The Infinium HumanCore BeadChip features highly-informative, genome-wide tag SNPs and additional high value markers such as indels and updated exome-focused content. The higher density Infinium HumanCoreExome BeadChip provides that same valuable core content, along with informative markers from the popular HumanExome BeadChip.

With array scanning performed using Illumina's HiScan® or iScan® systems, these multisample BeadChips are equally useful for efficiently and cost-effectively genotyping large populations, screening and quality control of samples prior to sequencing, or generating baseline genomic datasets of general sample cohorts.

“It's clear that large sample sizes are key to furthering progress in human genetics, and Illumina has been a partner to develop an array that will enable these studies,” said Mark McCarthy, Robert Turner Professor of Diabetes at the University of Oxford and an array design team member. “The HumanCoreExome BeadChip will be particularly valuable for research utilizing large sample studies. The combination of genome-wide tag SNPs and an enhanced set of exome markers, with the potential to add substantial custom content, will drive the next wave of association discovery for SNPs and CNVs.”

The new Infinium HumanCore BeadChips are available for immediate ordering. For more information, please visit http://www.illumina.com/corefamily.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com

 

Around the Web, We're Loving...

Get Benzinga's Newsletters